Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?

被引：43

作者：

Mangen, Marie-Josee J. ^{[1
,2
]}

van Duynhoven, Yvonne T. H. P. ^{[2
]}

Vennema, Harry ^{[2
]}

van Pelt, Wilfrid ^{[2
]}

Havelaar, Arie H. ^{[2
,3
]}

de Melker, Hester E. ^{[2
]}

机构：

[1] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands

[2] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands

[3] Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands

来源：

VACCINE | 2010年 / 28卷 / 14期

关键词：

Rotavirus vaccination; National immunization program; Cost-effectiveness; RISK-FACTORS; DISEASE BURDEN; GASTROENTERITIS; ENGLAND; HOSPITALIZATIONS; NETHERLANDS; INFECTIONS; EFFICACY; INFANTS; CAMPYLOBACTER;

D O I：

10.1016/j.vaccine.2010.01.014

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

This study assessed whether the inclusion of two rotavirus (RV) vaccines in the Dutch national immunization programme is cost-effective. Costs and outcomes in unvaccinated and vaccinated populations are compared for a time period of 20 years. In the baseline, assuming competitive market forces in relation to vaccine costs, Rotarix (R) is more cost-effective than RotaTeq (R), resulting in a cost-utility ratio (CUR) of (sic) 53,000 per DALY (third payer perspective) and (sic) 49,000 per DALY (societal perspective), but both considered as being not cost-effective. Vaccine-related costs, annual epidemic-size, and indirect protection are the major factors that determine cost-effectiveness of RV vaccination. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：2624 / 2635

页数：12

共 64 条

[41] Economic analysis of Campylobacter control in the Dutch broiler meat chain [J].

Mangen, Marie-Josee J. ;

de Wit, G. Ardine ;

Havelaar, Arie H. .

AGRIBUSINESS, 2007, 23 (02) :173-192

[42]

MANGEN MJJ, 2004, 250911004 NAT I PUBL

[43] Does Viral Diversity Matter? [J].

Medley, Graham F. ;

Nokes, D. James .

SCIENCE, 2009, 325 (5938) :274-275

[44] Cost and cost-effectiveness of childhood vaccination against rotavirus in France [J].

Melliez, H. ;

Levybruhl, D. ;

Boelle, P. Y. ;

Dervaux, B. ;

Baron, S. ;

Yazdanpanah, Y. .

VACCINE, 2008, 26 (05) :706-715

[45] Understanding DALYs [J].

Murray, CJL ;

Acharya, AK .

JOURNAL OF HEALTH ECONOMICS, 1997, 16 (06) :703-730

[46] Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study [J].

Murray, CJL ;

Lopez, AD .

LANCET, 1997, 349 (9063) :1436-1442

[47] The cost-effectiveness of rotavirus vaccination in Australia [J].

Newall, Anthony T. ;

Beutels, Philippe ;

Macartney, Kristine ;

Wood, James ;

MacIntyre, C. Raina .

VACCINE, 2007, 25 (52) :8851-8860

[48]

Oostenbrink J, 2004, Handleiding voor kostenonderzoek, methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg

[49]

Parashar Umesh D., 2006, Morbidity and Mortality Weekly Report, V55, P1

[50]

Phua KB, 2006, ANN ACAD MED SINGAP, V35, P38

← 1 2 3 4 5 6 7 →